Clinical trials
Polycystic Kidney Disease clinical trials
Below are recruiting polycystic kidney disease clinical trials, each written for real people, not researchers. We’re tracking 73 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07544524Recruiting
Plant-Based Diet for Kidney Disease in Asian Adults
This study tests whether eating mostly plants (with some animal products) can safely help people with moderate kidney disease. Researchers will compare this diet to a standard kidney-friendly diet and see how it affects kidney function and overall health.
SingaporeAges 21–79 - NCT06601829Recruiting
Liver and kidney disease study in children
This study looks at children with congenital hepatic fibrosis and autosomal recessive polycystic kidney disease. It aims to learn more about these conditions and how they affect children.
SohagAges Any age - NCT06902558RecruitingPhase 2
Study of ABBV-CLS-628 for adults with polycystic kidney disease
This trial tests a new drug, ABBV-CLS-628, for people with autosomal dominant polycystic kidney disease (ADPKD). The goal is to see if it slows kidney function decline and is safe to use.
Birmingham, AlabamaAges 18–55 - NCT07228364RecruitingPhase 1
Testing safety of AZD1613 for polycystic kidney disease
This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.
Birmingham, AlabamaAges 18–65 - NCT04782258RecruitingPhase 3
Testing the safety of tolvaptan in children with ARPKD
This trial is for children from 28 days old up to 18 years who have a rare kidney disease called ARPKD. It will test if the drug tolvaptan is safe for them. The study helps find new treatment options for kids with this condition.
Washington D.C., District of ColumbiaAges 4 weeks–18 years - NCT04344769Recruiting
Studying how a kidney-protecting pathway works in ADPKD
This study looks at how the body’s “Nrf2 response” works in people with autosomal dominant polycystic kidney disease (ADPKD). It may help researchers better understand disease biology and future treatments by comparing kidney-related signals in ADPKD patients and healthy volunteers.
Rochester, MinnesotaAges 18–30 - NCT04939935RecruitingPhase 3
Metformin to slow kidney decline in adults with polycystic kidneys
This Phase 3 study tests whether taking metformin can slow the decline of kidney function in adults with autosomal dominant polycystic kidney disease (ADPKD). You may be eligible if you have ADPKD and signs that your kidneys are starting to decline faster than expected.
Gosford, New South WalesAges 18–70 - NCT05476627Recruiting
Study risk factors for kidney disease from metabolic conditions
This study looks at risk factors and body “omics” information (like blood/tissue patterns) to better understand chronic kidney disease caused by metabolic diseases. It may help researchers find better ways to predict or manage kidney problems in people with these conditions.
Beijing, Beijing MunicipalityAges 18–80 - NCT05478083RecruitingPhase 2
Leuprolide treatment for severe polycystic liver growth
This Phase 2 study tests whether a monthly hormone medicine (leuprolide, a GnRH agonist given as an injection) can slow down ongoing, fast-growing polycystic livers. It is aimed at pre-menopausal women with very large livers that are still getting bigger on past and current scans.
Nijmegen, GelderlandAges 18–45 - NCT06065852Recruiting
National registry for rare kidney diseases
This study creates a registry to collect health information from people with rare kidney diseases. It aims to improve understanding and future treatments by tracking patient experiences.
Bristol, South WestAges Any age - NCT06291116RecruitingPhase 2
Safety of rotigotine patch for ADPKD patients
This study tests a skin patch called rotigotine to see if it is safe for people with ADPKD. It may help with blood pressure control, but you cannot have advanced kidney failure or certain other health issues.
AmiensAges 18–60 - NCT06325644Recruiting
Ketogenic diet for polycystic kidney disease
This study tests whether a ketogenic diet can slow the progression of polycystic kidney disease in adults who are at risk for rapid decline. You'll follow a carefully planned low-carb, high-fat diet to see if it helps protect your kidneys.
Columbus, OhioAges 18–65 - NCT06435858RecruitingPhase 2
SGLT2 inhibitor for calcium and magnesium in ADPKD
This study tests whether a medicine called an SGLT2 inhibitor (a type of diabetes drug) can help control calcium and magnesium levels in people with a genetic kidney disease called ADPKD. The goal is to see if it improves kidney health over a short period.
Zurich, Canton of ZurichAges 18–75 - NCT06618638Recruiting
Shared Decision Tool for ADPKD Treatment
This study helps people with ADPKD and moderate kidney damage decide together with their doctor whether to start a treatment called tolvaptan. It tests a shared decision-making tool to see if it helps patients understand their options better.
Anyang-si, Gyeonggi-doAges 18–80 - NCT06698614Recruiting
Magnetic resonance imaging to study kidney disease
This study uses a special MRI scan to look at the kidneys in people with different kinds of kidney disease, including acute kidney injury, chronic kidney disease, vasculitis, and after a kidney transplant. The goal is to better understand these conditions.
EdinburghAges 18 years+ - NCT06728228Recruiting
Amnioinfusion for fetal kidney failure
This trial is testing whether adding fluid back into the womb (amnioinfusion) can help babies whose kidneys are not working and who have no amniotic fluid early in pregnancy. It may improve the baby's chances of survival and lung development.
Dallas, TexasAges Any age - NCT06800651RecruitingPhase 2
A new drug for fast-growing polycystic kidney disease
This trial tests a drug (JMKX003142) for people with autosomal dominant polycystic kidney disease that is getting worse quickly. It may help slow down kidney damage.
Beijing, Beijing MunicipalityAges 18–55 - NCT06841692Recruiting
Diuretic testing for moderate kidney disease
This study checks how well diuretics (water pills) work in people with moderate chronic kidney disease. It may help doctors understand how to better treat fluid buildup in patients.
Rotterdam, South HollandAges 18 years+ - NCT06982079RecruitingPhase 3
SGLT2 inhibitors for advanced kidney disease
This trial tests whether SGLT2 inhibitor drugs can protect kidney function in people with advanced chronic kidney disease who are not yet on dialysis. It may help slow further kidney decline.
CairoAges 18 years+ - NCT07201025Recruiting
MRI study of kidney disease in ARPKD
This study uses MRI scans to track kidney disease progression in children and adults with ARPKD. It aims to better understand how the disease changes over time, which could help improve future care.
Cleveland, OhioAges 6 years+ - NCT07260071Recruiting
High blood pressure in kids at risk for inherited kidney disease
This study looks for early signs of high blood pressure in children and teens (12–17) who have a parent with ADPKD, a kidney condition. It uses non-invasive tests like blood pressure monitoring and MRI to track kidney health.
LondonAges 12–17 - NCT07280585RecruitingPhase 3
Testing a diabetes drug to slow kidney disease progression
This study tests whether a common diabetes medication (SGLT2 inhibitor) can help people with autosomal dominant polycystic kidney disease (ADPKD) maintain kidney function longer. If you have fast-growing kidney cysts and are between 18 and 60 years old, this trial may be an option.
FeldkirchAges 18–60 - NCT00792155Recruiting
Register people with diagnosed ADPKD to build a kidney data resource
This trial builds a secure database by collecting information from adults who already have autosomal dominant polycystic kidney disease (ADPKD). Your information can help researchers understand the condition better and improve future care.
New York, New YorkAges 18 years+ - NCT01401998Recruiting
Study collecting information from people with ARPKD
This study looks at medical records, imaging, and genetic testing for people with autosomal recessive polycystic kidney disease (ARPKD). It may help researchers better understand the condition and how it affects the liver and kidneys.
Washington D.C., District of ColumbiaAges Up to 18 years
Hear when a new Polycystic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for polycystic kidney disease?
- Yes. Clin2 currently lists 73 recruiting polycystic kidney disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a polycystic kidney disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a polycystic kidney disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.